NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP
Radiopharm Theranostics Limited RADX
3 fiscal years on record · USD · FY2024 reported
SEC FILINGS ONLY
Revenue · FY2024
$3.6M
▲ 1114.3% vs FY2023
EPS · FY24
$-1.76
Dividend / sh · FY24
—
Payout · FY24
—
ROE · FY24
—
Net margin · FY24
-1055.3%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 3.6M
Revenue, FY2024 · full 3-year series below
Revenue
Net income
The company lost 1055 cents on every revenue dollar this year.
Per share
USD -1.76
Diluted EPS, FY2024
EPS
The company pays no cash dividend.
Profitability
—
Return on equity, FY2024
ROE
Operating margin-1050.6%
Net margin-1055.3%
Return on assets-48.4%
Returned to shareholders
—
returned in FY2024 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
—
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Compound annual rates per period — left blank where the series crosses a loss.
Share base
—
Shares outstanding, FY2024
Change, 5 years—
Change, 10 years—
A share split breaks the comparison across the period, so we leave it out.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 86.5M
total assets, end of FY2024
Total assetsUSD 86.5M
CashUSD 29.1M
Current ratio2.67×
History
3 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2024
2023
2022
Revenue $B
0.0
0.0
0.0
Operating income $B
−0.0
−0.0
−0.0
EBITDA $B
·
·
·
Income tax $B
0.0
0.0
0.0
Net income $B
−0.0
−0.0
−0.0
EPS, diluted $
−1.76
−12.41
−11.32
Dividend / sh $
·
·
·
Payout %
·
·
·
ROE %
·
·
·
Shares out B
·
·
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
5 of 8
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 3 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed